Glycolysis regulated transglutaminase 2 activation in cardiopulmonary fibrogenic remodeling.

Autor: Bhedi CD; Pulmonary Division, Department of Medicine, Tufts Medical Center, Boston, MA, USA., Nasirova S; Pulmonary Division, Department of Medicine, Tufts Medical Center, Boston, MA, USA., Toksoz D; Pulmonary Division, Department of Medicine, Tufts Medical Center, Boston, MA, USA., Warburton RR; Pulmonary Division, Department of Medicine, Tufts Medical Center, Boston, MA, USA., Morine KJ; Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, USA., Kapur NK; Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, USA., Galper JB; Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, USA., Preston IR; Pulmonary Division, Department of Medicine, Tufts Medical Center, Boston, MA, USA., Hill NS; Pulmonary Division, Department of Medicine, Tufts Medical Center, Boston, MA, USA., Fanburg BL; Pulmonary Division, Department of Medicine, Tufts Medical Center, Boston, MA, USA., Penumatsa KC; Pulmonary Division, Department of Medicine, Tufts Medical Center, Boston, MA, USA.
Jazyk: angličtina
Zdroj: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2020 Jan; Vol. 34 (1), pp. 930-944. Date of Electronic Publication: 2019 Nov 28.
DOI: 10.1096/fj.201902155R
Abstrakt: The pathophysiology of pulmonary hypertension (PH) and heart failure (HF) includes fibrogenic remodeling associated with the loss of pulmonary arterial (PA) and cardiac compliance. We and others have previously identified transglutaminase 2 (TG2) as a participant in adverse fibrogenic remodeling. However, little is known about the biologic mechanisms that regulate TG2 function. We examined physiological mouse models of experimental PH, HF, and type 1 diabetes that are associated with altered glucose metabolism/glycolysis and report here that TG2 expression and activity are elevated in pulmonary and cardiac tissues under all these conditions. We additionally used PA adventitial fibroblasts to test the hypothesis that TG2 is an intermediary between enhanced tissue glycolysis and fibrogenesis. Our in vitro results show that glycolytic enzymes and TG2 are upregulated in fibroblasts exposed to high glucose, which stimulates cellular glycolysis as measured by Seahorse analysis. We examined the relationship of TG2 to a terminal glycolytic enzyme, pyruvate kinase M2 (PKM2), and found that PKM2 regulates glucose-induced TG2 expression and activity as well as fibrogenesis. Our studies further show that TG2 inhibition blocks glucose-induced fibrogenesis and cell proliferation. Our findings support a novel role for glycolysis-mediated TG2 induction and tissue fibrosis associated with experimental PH, HF, and hyperglycemia.
(© 2019 Federation of American Societies for Experimental Biology.)
Databáze: MEDLINE
Externí odkaz: